Evotec Responds to Halozyme Therapeutics' Takeover Proposal Amid Strategic Growth Efforts

Evotec SE, a German biotech company listed on both the Frankfurt Stock Exchange and NASDAQ, confirmed receiving an unsolicited, non-binding takeover proposal from Halozyme Therapeutics, a US-based biotechnology company. The offer, priced at €11.00 per share, values Evotec at approximately €2.1 billion. The company announced it will evaluate the proposal carefully and communicate further developments in compliance with legal obligations​.

This development comes during a transformative period for Evotec. The company recently reported mixed financial results for the first nine months of 2024, citing challenges in its Shared R&D segment but significant growth in its Just – Evotec Biologics division, which saw a 74% revenue increase. Evotec's strategic partnerships, including agreements with Sandoz, Pfizer, and Novo Nordisk, have strengthened its position in the biologics market, though ongoing restructuring efforts have temporarily impacted profitability​.

​

Halozyme's interest aligns with Evotec's reputation as a leader in integrated drug discovery and development, leveraging its proprietary technology platforms and extensive collaborations. The proposal highlights the increasing strategic value of Evotec's innovative approaches, particularly in biologics and shared R&D​.

Market analysts see this as part of a broader trend of consolidation in the biotech sector, with established companies seeking to enhance their pipelines through acquisitions. While Evotec has not committed to accepting Halozyme's offer, the proposal underscores its strategic importance in the industry​.

Further updates are expected as Evotec finalizes its analysis of the offer.